Medivation, Inc. (MDVN) has formally begun its phase III trial of the investigational drug MDV3100 with men who have advanced prostate cancer. The clinical trial known as AFFIRM will evaluate the novel androgen receptor antagonist, MDV3100, in men with castration-resistant prostate cancer who were previously treated with docetaxel-based chemotherapy. AFFIRM is a randomized, placebo-controlled, double-blind, [...]
One of the most heated debates in prostate cancer care is around the use of 5-reductase inhibitors (5ARI) like Dutasteride as a third component of a hormone blockade (ADT3). 5-ARIs block the conversion of testosterone to dihydrotestosterone (DHT). DHT is thought to be an extremely powerful “fuel” for the growth of prostate cancer. However, there [...]
The relatively new drug, denosumab, has proven itself very effective for men on a hormone blockade (ADT). In a recently completed 3-year, randomized, double-blind study at the Massachusetts General Hospital Cancer Center, Boston, Massachusetts, denosumab significantly increased bone mineral density and decreased new vertebral fractures in men receiving ADT for the treatment of advanced prostate [...]
Scott Goodwin who periodically has been writing about his journey taking chemotherapy has given us a very moving update. Sadly, Scott is not doing well physically, but he is continuing his valiant fight against this insipid disease. - JTN I thought I would send a much overdue update on my progress with chemo, etc. I [...]
A very scary study has been published in the journal BMC Emergency Medicine. The study found that sixty percent of the causes of unintended incidents in the emergency department that could have compromised patient safety are related to human failures. Human failures mean that the doctors, nurses or even orderlies did do something or did [...]